← SGLT2 inhibitors × cardiovascular events

SynthesisDiabetes, obesity & metabolism2022

Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.

Matthew R Weir et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 543 people · 2022

Randomised comparison

Probably lowered kidney outcomes

−29%−45% to −8%

Bigger than 6 in 10 on the map

As reported

HR 0.71, 95% CI 0.55–0.92

Randomised comparison

Probably reduced cardiovascular events

−17%−25% to −8%

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.83, 95% CI 0.75–0.92

Two numbers in the abstract

the abstract, start to end

… also reduced the risk of MACE (HR, 0.71; 95% CI, 0.55, 0.92), with no …

… risk of MACE compared with placebo (HR, 0.83; 95% CI, 0.75, 0.92), with no …

← favours treatmentfavours comparator →
could be chance
Kidney outcomes
HR 0.710.55–0.92
Cardiovascular events
HR 0.830.75–0.92
SGLT2 inhibitorsCardiovascular eventsKidney outcomes

SGLT2 inhibitors × cardiovascular eventshelps?mixed

unlikelylikely
0.50not counted

SGLT2 inhibitors × kidney outcomeshelps?settled

unlikelylikely
0.89not counted
← favours comparatorfavours treatment →
more certainless certain
1 / 5

2 papers cite it

2022
2023
2024
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 34463423